INTRODUCTION
Nephrotic syndrome (NS) is a multi-factorial clinical condition characterized by increased glomerular permeability with consequent massive proteinuria. There is a variable tendency towards developing edema, hypoalbuminemia and hyperlipidaemia. [1] The severity of lipid abnormalities also correlates with the degree of protienuria and a common complication in patients with chronic kidney disease and Nephrotic syndrome is proteinuria>3g/day. [2] The specific causes of nephrotic syndrome include minimal-change nephropathy, focal glomerulosclerosis, and membranous nephropathy. [1] It can also result from systemic diseases that affect other organs in addition to the kidneys, such as diabetes, amyloidosis, and lupus erythromatous. [1] Hyperlipidaemia is one of the cardinal manifestations of nephrotic syndrome. [3] Various studies have shown that the prevalence of hyperlipideamia or dyslipidaemia in patients with chronic kidney disease is higher than in the general population. [4] Nephrotics are at an increased risk for [5] [6] [7] but Ohta and his co-worker [8] reported high level of HDL while Alexander and his colleagues [9] reported low level of HDL in nephrotic patients. This disagreement in data is probably because in most patients the nephrotic syndrome is accompanied by renal failure or other systemic disorders such as diabetes mellitus (or both), or because the patients are receiving treatment such as corticosteroids, that has a confounding effects on the lipoprotein patterns. [6] It has also been shown that the incidence of nephrotic syndrome varies from place to place due to factors such as changes in food, habits, climate, type of work, and ethnic origin. [1] Also, certain factors like diet, malnutrition, genetic traits are known to alter the frequency and severity of lipid pattern in an individual. [1] Hence, this study sought to determine the lipid pattern of nephrotics in this locality and by extension (if any), determine the atherogenic index (AI), coronary risk index (CRI) and non-HDL cholesterol a surrogate marker of Apo-lipoprotein B of these patients.
METHODOLOGY Study population
Ninety six subjects comprising of forty eight certified nephrotics based on clinical manifestation and laboratory findings at the Nephrology and Paediatrics Clinic of the University of Benin Teaching Hospital (UBTH), and forty eight apparently healthy individuals without any clinical and laboratory findings of renal dysfunction, hypertension or systemic disease and non-smokers with age and sexmatched as controls were used for the study. Ethical clearance was obtained from the institution ethical committee and informed consent was obtained from patients.
Fasting venous blood samples were collected with minimum stasis into plain container. This was allowed to clot and spun in a centrifuge for 10 minutes. The serum was separated and kept frozen until required for analysis.
Biochemical assay
All parameters were assayed using standard methods. total cholesterol, [10] triglycerides, [11] HDL-cholesterol, [12] while others are by calculations LDL-cholesterol, VLDLcholesterol, [13] atherogenic index, coronary risk index [14] and non-HDL-cholesterol (Apo lipoprotein B surrogate marker). [15] Commercially available standard kits (Randox Laboratories, U.K) were used. Manufacturer's instructions were strictly adhered to.
Statistical analysis
The mean ± SD was calculated for each analyte and significant differences between means were determined using the student ttest. P<0.05 was considered the level of significance.
RESULTS
The mean ± SD and the statistical comparison of serum total cholesterol, triglycerides, HDL-C, LDL-C and VLDL-C are as shown in Table1. Table 2 shows the mean±SD of the atherogenic index (AI), coronary risk index (CRI) and non-HDL-C (Apo lipoprotein B surrogate marker). Figure 1 and 2 shows the mean±SD of total cholesterol, triglycerides, HDL-C, LDL-C, VLDL-C and AI,CRI, non-HDL-C in graphical form respectively. 
DISCUSSION
In our study, we observed hypercholesterolemia among nephrotics when compared with the control. This is in accordance with the work of various authors [1, [5] [6] [7] [8] [9] who did similar work on nephrotics. Vaziri [3] in his work attributed this hypercholesterolemia to a defective regulatory response of 3-hydroxy-3-methylglutararyl-coenzyme A (HMG-COA) reductase and hepatic cholesterol 7α-hydroxylase in nephrotics. These enzymes are rate-limiting enzymes in cholesterol biosynthesis and catabolism to bile acids in humans. There was also an increased level of triglycerides in nephrotics when compared with control. This is in agreement with the previous reports.
[ [5] [6] [7] This hypertriglyceridaemia observed in nephrotics is attributed to downregulation of lipoprotein lipase as found in nephrotics skeletal muscle, myocardium and adipose tissue, which is the principal sites of fatty acids consumption and storage. [3] The HDL-C level of nephrotics was significantly decreased when compared to the control in this study. This is in accordance with the findings documented in some studies. [9, 16] However, some conflicting findings exist which reported normal HDL-C in nephrotics, [5] [6] [7] while some reported high HDL-C in nephrotics. [8] A plausible explanation for the low level of HDL-C in nephrotics observed in the present study is the urinary losses of lecithin: cholesterol acyltransferase (LCAT) which leads to severe deficiency and limit the HDL-mediated uptake of surplus cholesterol from extra hepatic tissues. This is also compounded by marked reduction of the hepatic HDL-C receptor. [3] These limitations greatly affect the homeostasis of HDL-C in nephrotics. We also observed in this study increased level of LDL-C in nephrotics which is in agreement with previous studies. [1, [5] [6] [7] The increased LDL can be explained by severe reduction of hepatic LDL receptor protein abundance in nephrotics despite normal LDL receptor mRNA abundance and gene translation rate. [17] These findings point to inefficient translation and/or increased LDL receptor protein turnover as a cause of LDL receptor deficiency in nephrotic syndrome. [17] Given the critical role of LDL receptor, acquired LDL receptor deficiency will contribute to hypercholesterolemia, elevation of plasma LDL-C, and impaired LDL clearance [17] as found in nephrotics. The VLDL-C of nephrotics is elevated but not statistically significant when compared with the control subjects .This is in variance with the work of previous authors. [1, [5] [6] [7] The atherogenic index (AI), coronary risk index (CRI) and non-HDL-C in this study were observed to be elevated when compared with the control subjects. When the AI, CRI and Non-HDL of our study population were compared with the guidelines, the nephrotics seem to have unfavorable risk profile for cardiovascular disease. The recommended ratios for AI and CRI is ≤3.5, [14] while the AI observed in the study was 3.0±1.0 and 0.56±3.2 for nephrotics and control respectively, and CRI on the other hand was 4.8±1.7 and1.9±3.0 for nephrotics and controls respectively. The recommended value for non-HDL-C is <130mg/dl, [1, 15] nephrotics had a value of 192±11 while control had 88±12. These findings suggest that nephrotics may be at risk of cardiovascular disease.
Conclusively, attempts have been made in this study to establish serum lipid pattern in the Nigerian nephrotics and we have also been able to affirm that nephrotics experience hyperlipideamia which predisposes to cardiovascular disease. We therefore advocate that lipid profile should be among the hallmarks of the biochemical investigation including these indices for any nephrotic syndrome patient for better management.
